Efficacy and Safety of Dabigatran vs

Slides:



Advertisements
Similar presentations
The RE-LY Study: Randomized Evaluation of Long-term anticoagulant therapY Dabigatran Compared to Warfarin in 18,113 Patients with Atrial Fibrillation at.
Advertisements

JOURNAL REVIEW Newer Antithrombotics in AF 1 Dr Ranjith MP Senior Resident Department of Cardiology Government Medical college Kozhikode.
Georges Ghanem MD, FESC, FACC Associate Professor, Chief of Cardiology UMC-RH/LAU-SOM Beirut, Lebanon.
Concomitant Antiplatelet and OAC Tx: Real-World Practice In the US, ~800,000 AF patients are on concomitant OAC and antiplatelet tx 1 Patients on chronic.
Standard Medical Therapy TRA 40 mg mg/d TRA 40 mg mg/d Placebo EP:CV Death/MI/stroke/hosp for RI/urgent coronary revasc. 1  EP:CV Death/MI/stroke/hosp.
Guillaume Pare MD Genetic determinants of dabigatran plasma levels and their relation to bleeding On behalf of RE-LY Genetics: Guillaume Pare MD, Niclas.
Efficacy and Safety of Dabigatran vs. Warfarin in Patients with Atrial Fibrillation - Japanese population in the RE-LY ® - Shinya Goto, MD., PhD. Tokai.
ARISTOTLE TRIAL Dr R Nyabadza GPST1 Ward 32. Structure AF, stroke and CHA 2 -DS 2 VASC Anticoagulant choices ARISTOTLE trial Cost NICE guidance and the.
ARISTOTLE TTR Subanalysis
Efficacy and safety of apixaban compared with warfarin at different levels of INR control for stroke prevention in atrial fibrillation.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
The Definitive Thrombosis Update
Jim Hoehns, Pharm.D.. Edoxaban Oral factor Xa inhibitor Bioavailability: 62% Tmax: 1-2 hrs Elimination: 50% renal Half-life: 9-11 hours.
Randomized Evaluation of Long- term anticoagulant therapY Dabigatran Compared to Warfarin in 18,113 Patients with Atrial Fibrillation at Risk of Stroke.
Atrial Fibrillation Warfarin and its newer alternatives
ROCKET AF Renal Dysfunction Substudy Objective Evaluate the 2950 patients in the per-protocol cohort with a baseline CrCl of 30 to 49 mL/min who received.
  Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban Target
The Long Term Multi-Center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation (RELY-ABLE) study To reviewers and moderators: These.
ACTIVE Clopidogrel plus Aspirin versus Aspirin in Patients Unsuitable for Warfarin.
UK/CVS (1) | February 2013 Emerging technologies for stroke prevention in atrial fibrillation UK/CVS (1) | Date of preparation: February 2013.
Atrial Fibrillation Management Past, Present and Future
Guillaume Pare MD Genetic determinants of dabigatran plasma levels and their relation to bleeding On behalf of RE-LY Genetics: Guillaume Pare MD, Niclas.
Atrial Fibrillation Management Past, Present and Future
S. Goto1, J. Zhu2, L. Lisheng2, BH. Oh3, D. Wojdyla4, M. Hanna5, J. Horowitz6, L. Wallentin7, D. Xavier8, JH. Alexander4 (1) Tokai University School of.
A Randomized Trial of Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism Schulman S et al. Proc ASH 2011;Abstract 205.
Update in ESC: Dabigatran among OAC
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
The ACTIVE Investigators. N Engl J Med 2009 Apr 3 [Epub]
Presented by Renato D. Lopes, MD, PhD, Duke Clinical Research Institute, Duke University, USA for the ARISTOTLE investigators. Efficacy and Safety of Apixaban.
Shinya Goto,1 Jun Zhu,2 Liu Lisheng,2 Byung-Hee Oh,3 Daniel M. Wojdyla,4 Michael Hanna,5 John D. Horowitz,6 Lars Wallentin,7 Denis Xavier,8 John H. Alexander4.
N Engl J Med 2009;361: Stuart J. Connolly, M.D., Michael D. Ezekowitz, M.B., Ch.B., D.Phil., Salim Yusuf, F.R.C.P.C., D.Phil., John Eikelboom,
The Management of AF Warfarin New anticoagulants 16 Sept 2011.
Net clinical benefit of OAC
Response to An Initial Dose of Warfarin in Thai Patients Undergoing Long-Term Anticoagulant Therapy Weerayuth Saelim R.Ph. 2 nd year Pharmacy resident.
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.
Review on NOACs Studies DR. KOUROSH SADEGHI TEHRAN UNIVERSITY OF MEDICAL SCIENCES.
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective by Michael D. Ezekowitz, Rangadham.
The Efficacy of Dabigatran versus Warfarin for Stroke Prevention in Patients With Atrial Fibrillation: Systematic Review Karim Bouferrache Pacific University.
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,
Stroke, Bleeding, and Mortality Risks in Elderly Medicare Beneficiaries Treated with Dabigatran or Rivaroxaban for Nonvalvular Atrial Fibrillation.
Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Non-valvular Atrial Fibrillation.
Harvard Medical School C. Michael Gibson, M.S., M.D.
David R. Holmes, Jr., M.D. Mayo Clinic, Rochester
A Comparison of RE-LY and ROCKET AF Trial Designs and Outcomes
Polypharmacy Anticoagulation: AF meets PCI
A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The Randomized, phase II study to Evaluate the sAfety and.
SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.
Anticoagulation in Atrial Fibrillation
Management of AF­related stroke
No evidence that AF type significantly impacts stroke risk
RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.
Randomized Evaluation of Long-term anticoagulant therapY
Novel oral anticoagulants in comparison with warfarin
Click here for title Click here for subtitle
ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.
Timothy A. Brighton, M. B. , B. S. , John W. Eikelboom, M. B. , B. S
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD,
The Safety and Efficacy of Full vs
Up to Date on Which NOAC for Which Patient
Dabigatran vs Warfarin in Patients with Atrial Fibrillation – Results
Relative Risk of Events by CHA2DS2-VASc Score
Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial Renato D. Lopes, MD, PhD on behalf of the.
Probability of major bleeding event and ischaemic stroke/SEE versus trough plasma concentration of dabigatran. Calculated for a 72-year-old male patient.
5 Good Minutes on Atrial Fibrillation-related Stroke
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter 
Probability of major bleeding event and ischaemic stroke/SEE versus trough plasma concentration of dabigatran. Calculated for a 72-year-old male patient.
(p for noninferiority = 0.01)
Presenter Disclosure Information
The CHA(2)DS2-(VASc) stroke risk and HAS-BLED bleeding risk index are calculated by totalling the scores for each risk factor present.68–71 The lower graph.
Presentation transcript:

Efficacy and Safety of Dabigatran vs Efficacy and Safety of Dabigatran vs. Warfarin in Patients with Atrial Fibrillation - Japanese population in the RE-LY ® - Shinya Goto , MD., PhD. Tokai University School of Medicine C. Michael Gibson, M.S., M.D. Beth Israel Deaconess Medical Center, Harvard Medical School, Duke Clinical Research Institute

RE-LY® - Overall Summary Dabigatran etexilate has been shown to concurrently reduce both thrombotic and haemorrhagic events Both doses of dabigatran provide different and complementary advantages over warfarin 150 mg BID showed 35% statistically significant reduction in stroke/systemic embolism with similar bleeding 110 mg BID showed comparable rates of stroke/systemic embolism has significantly less bleedings with similar efficacy

RE-LY® - Baseline Characteristics in Japanese Subjects Overall Japan Randomized 18,113 326 Mean age (years) 71.5 71.2 Male (%) 63.6 76.7 CHADS2 score (mean) 0-1 (%) 2 (%) 3+ (%) 2.1 31.9 35.6 32.5 2.2 31.3 34.0 34.7 Prior stroke / SEE / TIA(%) 21.8 33.1 Prior MI (%) 16.6 5.5 CHF (%) 32.0 31.0 Baseline ASA (%) 39.8 35.9 VKA naive (%) 50.4 56.1 Over all : calculated from NEJM, 2009, 361, 12 Hori M, et al: Circ J 2011; 75: 800 - 805, 2011

RE-LY® - Stroke or Systemic Embolism Overall Japan % per year 150mg bid 110mg bid (n=134/6,076) (n=183/6,015) (n=202/6,022) % per year 150mg bid 110mg bid (n=1/111) (n=12/107) (n=4/108) RR 0.65 (95% CI: 0.52-0.81) RR 0.25 RR 0.90 (95% CI: 0.74-1.10) RR 0.52 Connolly SJ, et al.: N Engl J Med 363, 1875-1876, 2010 Hori M, et al: Circ J 2011; 75: 800 - 805, 2011

RE-LY® - Plasma Concentration of Dabigatran in Overall and Japanese Overall Japanese Overall Japanese Cpre,ss: Pre dose plasma concentrations at steady state C2,ss : Plasma concentration at 2 hours after drug administration at steady state (approximate maximum plasma concentration) Hori M, et al: Circ J 2011; 75: 800 - 805, 2011

Country Distribution of Mean Time in Therapeutic Range (TTR) in the RE-LY® Wallentin L, et al.: Lancet, 376: 975-83, 2010

RE-LY® - INR Control / Time racio Region N INR <2 INR 2-3 INR>3 Overall 5,789 22.2% 64.4% 13.5% Japan 108 36.8% 57.6% 5.6% JCS guideline for pharmacotherapy of atrial fibrillation2008: 2.0~3.0 for <70 years 1.6~2.6 for ≧70 years Over all : calculated from NEJM, 2009, 361, 12

RE-LY® - Japanese Population Conclusions The result of Japanese subgroup is basically consistent with overall results of RE-LY®. The demographics of the Japanese subgroup differ from the overall population in prior stroke and MI of RE-LY but the overall risk score is similar. PK profile between Japanese subgroup and overall is similar. Based on the Japanese guideline criteria, the INR control of warfarin was well-controlled.